insulin degludec vs insulin detemir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin degludec · Tresiba

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT00982644 · Phase 3 · completed

The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)

Result source: NCT00982644

insulin detemir · Levemir

Rights held by Novo Nordisk; US product discontinued

Approved in Type 2 Diabetespeptide
Partial signal

NCT00283751 · Phase 3 · completed

The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00856986

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin degludecinsulin detemir
HbA1c, change-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
Body weight, change (kg)2.9 vs -1vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
-0.1 vs -1.0vs Lira 1.8wk 52 · n 162NCT00856986
8 other results
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • 3.6 vs 6.4 wk 156 · n 234 · Phase 3 · secondary NCT00184600
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396
HbA1c below 7%75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116—Not posted · NCT00604396
Fasting plasma glucose, change-4.1 vs -2.6vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
3-point MACE (% with event)—Not posted · NCT05802862—Not posted · NCT00604396

HbA1c, change

insulin degludec
-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
insulin detemir
-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684

Body weight, change (kg)

insulin degludec
2.9 vs -1vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
insulin detemir
-0.1 vs -1.0vs Lira 1.8wk 52 · n 162NCT00856986
8 other results
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • 3.6 vs 6.4 wk 156 · n 234 · Phase 3 · secondary NCT00184600
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396

HbA1c below 7%

insulin degludec
75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116
insulin detemir
—Not posted · NCT00604396

Fasting plasma glucose, change

insulin degludec
-4.1 vs -2.6vs Liraglutidewk 52 · n 275NCT02607306
15 other results
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
insulin detemir
-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335

3-point MACE (% with event)

insulin degludec
—Not posted · NCT05802862
insulin detemir
—Not posted · NCT00604396
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. insulin degludec: 10 of 10 rows · insulin detemir: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin degludec
Rows use multiple source trials
insulin detemir
Rows use multiple source trials
BMI
absolute change · kg
0.43 vs 0.4 NovoRapid kg @ 16wka,b,c,d
NCT03268005 · Phase 3 · registry result, not featured evidence
0.2 vs 0.3 Insulin Detemir kg @ 26wka,b,c,d
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
1 other source trial
-0.3 vs -0.58 Sitagliptin kg @ 26wk
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
HbA1c
absolute value · percentage points
8.2% (n=72) vs 7.4% (n=59) Glargine @ 12wke,b,c,f
NCT03336528 · Phase 4 · registry result, not featured evidence
7.11% (n=234) vs 7.04% (n=239) Insulin Aspart @ 156wke,b,c,f
NCT00184600 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=200) @ 32wkg,a,b,c,h
NCT02298192 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.01% (n=189) @ 32wk
NCT02298192 · Phase 3 · registry result, not featured evidence
-1% (n=21) @ 20wkg,a,b,c,h
NCT01868542 · Phase 4 · registry result, not featured evidence
show 1 more dose
-0.9% (n=23) @ 20wk
NCT01868542 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
63% (n=292) vs 22.6% (n=146) Liraglutide or Exenatide @ 26wkb,c,i
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
43.2% (n=234) vs 44.8% (n=239) Insulin Aspart @ 156wkb,c,i
NCT00184600 · Phase 3 · registry result, not featured evidence
SMPG 9-point
absolute value · mmol/L
Before breakfast
5.66 vs 6.89 Liraglutide mmol/L @ 26wkg,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
5.41 vs 6.89 Liraglutide mmol/L @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
6.16 vs 8.17 Sitagliptin mmol/L @ 26wkb,c
Before breakfast
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
Waist Circumference Change
absolute change · cm
1.2 vs -2.6 Liraglutide cm @ 26wkg,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.3 vs -2.6 Liraglutide cm @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-0.78 vs -0.66 Lira 1.8 cm @ 26wkb,c
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
Dropout rate
21.5%once dailyj
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
2%
NCT01959529 · Phase 3
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
2.7%
NCT04795531 · Phase 3 · registry result, not featured evidence
6.7%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
8.5%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
0%k
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.7%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
13.9%
NCT01165684 · Phase 4 · registry result, not featured evidence
16.7%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
6.9%
NCT00455858 · Phase 4 · registry result, not featured evidence
12.3%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
14.8%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
19.2%
NCT00184600 · Phase 3 · registry result, not featured evidence
12.6%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
18.2%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
15.1%
NCT01837680 · Phase na · registry result, not featured evidence
Discontinued due to AEs
2.6%once dailyj
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
0%
NCT01959529 · Phase 3
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
—
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
—
NCT04795531 · Phase 3 · registry result, not featured evidence
0.6%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
—
NCT03268005 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
2.2%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
0.3%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
0%k
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
—Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
0.5%
NCT01165684 · Phase 4 · registry result, not featured evidence
2.2%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
—
NCT00591227 · Phase 4 · registry result, not featured evidence
—
NCT00455858 · Phase 4 · registry result, not featured evidence
1.6%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
2.5%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
—
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
3.8%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.8%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
—Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
—Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
—
NCT01837680 · Phase na · registry result, not featured evidence
Serious AEs
15.1%once dailyj
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
38.6%
NCT01959529 · Phase 3
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
3.7%
NCT03336528 · Phase 4 · registry result, not featured evidence
6.7%
NCT04588259 · Phase 3 · registry result, not featured evidence
5.1%
NCT04795531 · Phase 3 · registry result, not featured evidence
4%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
20.8%
NCT03078478 · Phase 3 · registry result, not featured evidence
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.8%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
—Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
3.1%Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT01570751 · Phase 3 · registry result, not featured evidence
10.4%k
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
4.3%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
9.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
3.1%
NCT00909480 · Phase 4 · registry result, not featured evidence
0%
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
4.1%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
3.3%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
0%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
22.4%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
33.3%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.9%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
0%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
0%
NCT01837680 · Phase na · registry result, not featured evidence
Most frequent reported AEs
once dailyj
nasopharyngitis 23.9%
headache 13.8%
diarrhoea 10.8%
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 23 more results
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
emergency room visit for bilateral knee pain 1.2%
emergency room visit for congestive heart failure 1.2%
emergency room visit for wound infection 1.2%
NCT03336528 · Phase 4 · registry result, not featured evidence
diabetic retinopathy 14.7%
hyperlipidaemia 14%
upper respiratory tract infection 9.3%
NCT04588259 · Phase 3 · registry result, not featured evidence
covid-19 4.8%
influenza 3.1%
diabetic retinopathy 2%
NCT04795531 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.7%
nasopharyngitis 5.1%
diabetic retinopathy 3.4%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
nasopharyngitis 19%
upper respiratory tract infection 18.1%
diarrhoea 9%
NCT03078478 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 33.6%
weight increased 7%
pharyngitis 5.5%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
lipase increased 10%
headache 9.3%
nasopharyngitis 8.9%
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 1.4%
NCT01570751 · Phase 3 · registry result, not featured evidence
k
nasopharyngitis 20.2%
nausea 18.4%
diarrhoea 17.8%
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
nasopharyngitis 13%
headache 8.7%
upper respiratory tract infection 4.3%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 13%
rash 8.7%
upper respiratory tract infection 8.7%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 8.1%
headache 5.1%
influenza 5.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
nasopharyngitis 10.6%
upper respiratory tract infection 8%
headache 7.5%
NCT00909480 · Phase 4 · registry result, not featured evidence
nasopharyngitis 11.5%
upper respiratory tract infection 5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
back pain 5.8%
headache 5%
upper respiratory tract infection 5%
NCT00634842 · Phase 4 · registry result, not featured evidence
pain in extremity 3.3%
urinary tract infection 3.3%
anxiety 2.5%
NCT00634842 · Phase 4 · registry result, not featured evidence
nausea 11.1%
diarrhoea 5.6%
hypertension 5.6%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 46.2%
diarrhoea 25.6%
infection 21.4%
NCT00184600 · Phase 3 · registry result, not featured evidence
headache 14.5%
nasopharyngitis 13.2%
back pain 10.5%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
gastrointestinal intolerance 0%
NCT01232946 · Phase na · registry result, not featured evidence
gastrointestinal intolerance 18.2%
NCT01232946 · Phase na · registry result, not featured evidence · combination
biochemical event of hypoglycemia 50.9%
symptomatic hypoglycemia 30.2%
symptomatic nocturnal event 15.1%
NCT01837680 · Phase na · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 26 weeks versus 16 weeks.
  5. eTrial phases differ: Phase 3 versus Phase 4.
  6. fAssessment timepoints differ: 156 weeks versus 12 weeks.
  7. gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  8. hAssessment timepoints differ: 20 weeks versus 32 weeks.
  9. iAssessment timepoints differ: 156 weeks versus 26 weeks.
  10. jPopulation comparability has not been reviewed for 25 of these studies.
  11. kPopulation comparability has not been reviewed for 16 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin degludec

Time to First MACE 8.5% (n=3818) vs 9.3% (n=3819) Insulin Glargine
event count · % of participants
First EAC-confirmed MACE
NCT01959529 · Phase 3 · converted to % from 325 Participants as posted
Non-fatal MI 3.7% (n=3818) vs 4.3% (n=3819) Insulin Glargine
event count · % of participants
Myocardial infarction (non-fatal)
NCT01959529 · Phase 3 · converted to % from 143 Participants as posted
Stroke 1.8% (n=3818) vs 1.9% (n=3819) Insulin Glargine
responder rate · % of participants
Stroke (non-fatal)
NCT01959529 · Phase 3 · converted to % from 68 Participants as posted
CV Death 3% (n=3818) vs 3.1% (n=3819) Insulin Glargine
responder rate · % of participants
Cardiovascular death
NCT01959529 · Phase 3 · converted to % from 114 Participants as posted
Hypoglycemia Episodes Level 3 280 vs 472 Insulin Glargine count
event count · count
NCT01959529 · Phase 3
show 2 more results
2 vs 0 Insulin Icodec count @ 31wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0 vs 0 Insulin Icodec count @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
Hypoglycemia Event Incidence 4.9% (n=3818) vs 6.6% (n=3819) Insulin Glargine
event rate · % of participants
NCT01959529 · Phase 3 · converted to % from 187 Participants as posted
HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Daily Glucose mg/dL 9.98 vs 10.03 Glargine mmol/L @ 1wk
absolute value · mmol/L
Day 1 up to Day 10
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 179.75 mg/dL as posted
Daily Glucose mg/dL 8.71 vs 7.94 Glargine mmol/L @ 4wk
absolute value · mmol/L
Day after discharge up to the 4 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 157 mg/dL as posted
Daily Glucose mg/dL 8.25 vs 7.43 Glargine mmol/L @ 12wk
absolute value · mmol/L
4 week post-discharge up to the 12 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 148.7 mg/dL as posted
Clinically Significant Hypoglycemia Event Incidence 3.7% (n=82) vs 1.3% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
Severe Hypoglycemia Event Incidence 0% (n=82) vs 0% (n=79) Glargine
event rate · % of participants
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted

+ 102 further endpoints in the CSV export.

insulin detemir

Waist Circumference Change -0.83% (n=160) vs -0.83% (n=148) Lira 1.8 @ 52wk
absolute change · percentage points
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -4.12 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -74.3 mg/dL as posted
show 3 more results
-2.48 mmol/L @ 12wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -44.6 mg/dL as posted
-3.35 mmol/L @ 20wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -60.4 mg/dL as posted
-3.89 mmol/L @ 20wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -70 mg/dL as posted
HbA1c Less Than 7 19.2% (n=193) vs 56.3% (n=183) insulin aspart @ 10wk
absolute value · percentage points
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
45.1% (n=195) vs 65.4% (n=188) insulin aspart @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 7.1 vs 6.7 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 5 more results
7.1 vs 7 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
7.12 vs 7.01 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
6.22 vs 6.09 IGlar mmol/L @ 26wk
NCT00909480 · Phase 4 · registry result, not featured evidence
6.08 vs 8.52 Sitagliptin mmol/L @ 26wk
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
5.4 vs 5.59 Insulin NPH mmol/L*
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 97.3 mg/dL as posted
Postprandial Glucose Increment 2.3 vs 1.4 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
1.9 vs 1.5 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
1.64 vs 1.28 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Body Weight 89.32 vs 89.8 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
BMI 31.86 vs 32.03 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
HbA1c 7 0 or Less 38% (n=209) vs 53% (n=204) IGlar @ 26wk
responder rate · % of participants
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 Without Hypoglycemia 32% (n=209) vs 38% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6 5 11% (n=209) vs 21% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6 5 Without Hypoglycemia 9% (n=209) vs 15% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence
Glucose Variability SD 0.57 vs 0.71 IGlar mmol/L @ 26wk
absolute value · mmol/L
Overall
NCT00909480 · Phase 4 · registry result, not featured evidence

+ 27 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · insulin detemir's landscape